CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 287 enrolled
Drug / intervention
RN624 (PF-04383119)drug
Likely dose
RN624 (PF-04383119) 50 mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00399490
NCT00399490Phase 2Completed
CompareCT.gov

OPEN-LABEL, MULTIPLE-DOSE STUDY OF THE SAFETY AND EFFICACY OF RN624 IN ADULTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE.

Pfizer·interventional·Posted Nov 15, 2006·Updated Feb 2, 2021

In Brief

A Phase 2 clinical trial evaluating RN624 (PF-04383119) for Osteoarthritis and 2 related conditions. Completed, enrolled 287 participants across 36 sites.

Detailed Summary

Study RN624-CL007 is planned to be an open-label protocol to enroll subjects who have previously participated in Study No. RN624-CL006. In this study, subjects will receive RN624 on an open-label basis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis, OA Knee Pain, Arthritis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 15, 2006
Enrollment StartSep 15, 2006
Primary CompletionFeb 11, 2008
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 19.6 years ago

Interventions

RN624 (PF-04383119)drug

50 mcg/kg